Hadden RDM, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015;8(1):14-19.
Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836-842.
Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy. 2014;6(1):71-83.
Data on File. Available from CSL Behring as DOF HIZ-005.
van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomised double-blind placebo-controlled trial: the PATH Study. Lancet Neurol. 2017;17(1):35-46.
Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.
Jolles S, Borte M, Nelson R, et al. Long-term efficacy, safety, and tolerability of Hizentra for treatment of primary immunodeficiency disease. Clin Immunol. 2014;150(2):161-169.
Data on File. Available from CSL Behring as DOF HIZ-006.
Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-414.
US Department of Health & Human Services, Centers for Medicare & Medicaid Services. International Classification of Diseases, Tenth Revision, Clinical Modifications (ICD-10-CM). 2018 Codes Tables and Index. https://www.cdc.gov/nchs/icd/icd10cm.htm. Accessed March 16, 2018.
American Medical Association. Medicine/hydration, therapeutic, prophylactic, diagnostic injections and infusions, and chemotherapy. In: American Medical Association, ed. CPT 2016. Chicago, IL: American Medical Association; 2016:650-651.
US Department of Health and Human Services, Centers for Medicare & Medicaid Services. HCPCS Release & Code Sets. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Al pha-Numeric-HCPCS-Items/2018-Alpha-Numeric-HCPCS-File-.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=descending. Accessed March 16, 2018.
Murphy E, Burton J, Riley P. Nursing approaches to a novel subcutaneous immunoglobulin therapy. Infusion. 2007;13:1-8.
Van Schaik IN, Orell N, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. Neural Neuroimmunol Neuroinflamm. 2019;6:e590.